The existence and market status of generic drugs of Apelvis

Alpelisib (Alpelisib), a drug that has been marketed in many overseas countries, provides a new treatment option for patients with advanced or metastatic breast cancer with certain mutations. Recent news shows that generic drugs of Apelvis have also quietly entered the market. These generic drugs are highly similar to Apelvis in terms of drug ingredients, but there may be certain differences in production specifications and prices. For example, Lucius Pharmaceutical Factory in Laos is one of the many manufacturers that produces generic drugs of Apelvis. The price of the 150mg*28 tablets they produce is about more than 2,000 yuan. Of course, this price may fluctuate due to factors such as exchange rates.

Apelixis, as a type of phosphoinositide 3-kinase (PI3K) inhibitor, is mainly targeted at HR-negative, HER2-negative breast cancer patients, especially those menopausal male and female patients whose cancer has progressed or metastasized to other organs. When used in combination with fulvestrant (Faslodex), Apelvis can more effectively control breast cancer that has spread to nearby tissue or other parts of the body. Its core component, piqray, helps prevent further spread of cancer cells in the body by inhibiting the signaling pathways that cause cancer cells to multiply.

Apelix usually comes in the form of film-coated tablets, available in three strengths: 50 mg, 150 mg and 250 mg. Plasma concentrations of apelix will reach a steady state approximately 3 days after administration. Research data show that apelixis is moderately bound to plasma proteins and is evenly distributed between plasma and red blood cells. At steady state, its dispense volume is approximately 114 liters.

For patients, the emergence of generic drugs undoubtedly provides more choices. However, when choosing to use generic drugs, patients and doctors still need to carefully evaluate their efficacy and safety to ensure that the therapeutic effect is maximized.